ClinicalTrials.gg
Active, not recruitingNCT07479797Updated Oct 26, 2026

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

A Phase 3 interventional study of KITE-753 and Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company. Active, not recruiting at 42 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 3, Interventional, and Treatment

Updated Oct 26, 2026Now Active, not recruitingFirst sites in 5 new countries+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy.

The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.

02

Conditions studied

  • Relapsed or Refractory Large B-cell Lymphoma

Browse trials for

03

In context

Lead sponsor

Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

First submitted after Kite became part of Gilead Sciences.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals with any of the following large B-cell lymphomas, as determined by the investigator, are eligible for the study as defined below:

    • World Health Organization (WHO):

      • Individuals with chemorefractory disease to therapy (primary disease) that satisfies any of the following criteria:

        • Progressive disease (PD) and/or Deauville score of 5 (irrespective of the response designation) as the best response during the first-line treatment or as the end of treatment response following first-line therapy.
        • Stable disease (SD) after at least 4 cycles of first-line therapy (eg, 4 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)).
        • PR as best response after at least 6 cycles of first-line therapy (eg, 6 cycles of R-CHOP).
        • Note: A is recommended to confirm residual disease.
      • Individuals with relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven disease relapsed ≤ 12 months of completion of first-line therapy.
      • Note: If the relapse is confirmed by imaging per International Working Group (IWG) Lugano Response Criteria for Malignant Lymphoma within 12 months, the confirmatory biopsy must be performed within 90 days of the 12-month cutoff.
      • Prior therapy must have included an anti-CD20 antibody (including CD20-targeting T-cell engager antibodies) and an anthracycline-containing chemotherapy regimen.
      • For individuals with transformed indolent NHL, therapies given for non-transformed disease do not count as a line of therapy for the transformed disease.
      • Individuals who have had no additional systemic therapy or holding therapy (except for and/or local radiation) following first-line therapy and prior to leukapheresis are eligible.
  • At least 1 according to the IWG Lugano Response Criteria. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy. A measurable lesion is defined as >1.5 cm longest transverse diameter (LDi) for lymph node and > 1.0 cm LDi for extranodal lesion. Splenomegaly or hepatomegaly alone in the absence of a measurable lesion is not considered to be measurable disease.
  • The following must be satisfied:

    • At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the individual is randomized.
  • Toxicities due to immediate prior therapy must have recovered to Grade 1 or lower (except for clinically nonsignificant toxicities such as alopecia, unless otherwise specified in the protocol)
  • (ECOG) performance status of ≤ 2.
  • Adequate bone marrow function as evidenced by:

    • ≥ 1,000/μL or ≥ 500/μL if documented bone marrow involvement of lymphoma. Bone marrow involvement by lymphoma is demonstrated by positron emission tomography (PET) scan or bone marrow aspiration or bone marrow biopsy.
    • count ≥ 75,000/μL (unless secondary to bone marrow or spleen involvement by lymphoma, in which platelet count ≥ 50,000 μL is permitted). Bone marrow involvement by lymphoma is demonstrated by PET scan or bone marrow aspiration or bone marrow biopsy. Spleen involvement by lymphoma is demonstrated by PET-diagnostic computed tomography (CT) involvement, splenomegaly, or biopsy.
  • Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:

    • Creatine clearance (as estimated by formula) ≥ 30 mL/minute. Note: 24-hour urine estimate is also acceptable.
    • Serum /aspartate aminotransferase ≤ 3.0 times the , except in individuals with documented liver involvement by lymphoma via PET-diagnostic CT scan or biopsy
    • Total ≤ 1.5 mg/dL, except in individuals with Gilbert's Syndrome or documented liver or pancreatic involvement where ≤ 3.0 times the upper limit of normal is permitted
    • Cardiac ≥ 40% and no pericardial effusion Grade 3 or higher (per (CTCAE) version (v)5.0) as determined by an echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) (if ECHO not available at the site). Note: If there is any concern for pericardial effusion, an ECHO must be performed since MUGA alone is not an adequate modality to assess for pericardial effusion.
    • No evidence of Grade 2 (per CTCAE v5.0) or greater pleural effusion or ascites (individuals with Grade 1 ascites or pleural effusion are eligible)
    • Baseline oxygen saturation > 92% on room air
  • Females of must have a medically supervised negative serum or urine pregnancy test (females who have undergone surgical sterilization or have been for at least 2 years before randomization are not considered to be of childbearing potential.

Key Exclusion Criteria:

  • Prior CAR T-cell therapy or other cell-based therapy.
  • History of other than nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder, or breast) unless disease-free and without anti-cancer therapy (with the exception of hormonal therapy in the case of breast cancer) for at least 3 years. Individuals with asymptomatic localized low-grade prostate cancer for which a watch-and-wait approach is standard of care are eligible.
  • Individuals with the following LBCL fifth edition of WHO criteria subtypes: Richter's transformation of chronic leukemic lymphoma, small lymphocytic lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, T-cell/histiocyte-rich LBCL, mediastinal gray zone lymphoma, plasmablastic lymphoma, intravascular LBCL, primary central nervous system (CNS) lymphoma, primary vitreoretinal LBCL, fibrin-associated LBCL, fluid overload-associated LBCL lymphomatoid granulomatosis, high-grade B-cell lymphoma (HGBCL) with 11q aberrations, anaplastic lymphoma kinase-positive LBCL, LBCL with Interferon Regulatory Factor 4 (IRF4) rearrangement, and transformed from Hodgkin's lymphoma (HL). Note: Individuals with primary testicular LBCL are eligible.
  • History of a severe, immediate reaction attributed to aminoglycosides
  • Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requires intravenous (IV) antimicrobials for management. Note: Simple urinary tract infections and uncomplicated bacterial or viral upper respiratory tract infections are permitted if the individual is responding to active treatment and satisfies the criteria of being afebrile for 48 hours (ie, temperature \< 38°C).
  • Known history of virus (HBV) (hepatitis B surface (HBs) antigen (HBsAg) positive) infection, or (anti-hepatitis C virus (HCV)) positive) infection. History of a hepatitis B or C infection is permitted if the viral load is undetectable per quantitative polymerase chain reaction (qPCR) or nucleic acid testing. Note: Individuals who are seropositive for HBV (ie, HBs and/or hepatitis B core antibody positive) are eligible if they are HBsAg-negative and negative for viral DNA. Individuals who are seropositive because of HBV vaccination are eligible (ie, HBs antibody positive, hepatitis core antibody-negative, and HBsAg-negative). Individuals on prophylactic and suppressive antiviral medications against HBV and/or HCV administered per institutional or clinical practice guidelines are eligible.
  • -positive, unless taking appropriate anti-HIV medications, with an undetectable viral load by qPCR and a ≥ 200 cells/μL. Note: HIV-positive individuals in Australia are not permitted regardless of active antiretroviral therapy or undetectable blood viral load.
  • History or presence of the following CNS disorders: hemorrhage, dementia (per CTCAE v5.0 Grade 2 or higher memory impairment), cerebellar disease, any disease with CNS involvement, posterior reversible encephalopathy syndrome, or cerebral edema with confirmed structural defects by appropriate imaging.
  • History of stroke or within 6 months before enrollment. Individuals with seizure disorders requiring active anticonvulsive medication.
  • Individuals with cardiac atrial or cardiac ventricular lymphoma involvement.
  • Individuals with secondary CNS lymphoma.
  • Individuals with full thickness lymphoma involvement of gastric or intestinal lining. Individuals with concern for gastric or intestinal perforation or known contained perforation.
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, active unstable/uncontrolled arrhythmia, Class II or greater congestive heart failure, or other cardiac disease within the 6 months before enrollment.
  • Requirement for urgent therapy within 4 weeks before enrollment due to ongoing or impending oncologic emergency (eg, tumor mass effect)
  • Presence of primary immunodeficiency.
  • History of any medical condition including but not limited to autoimmune disease (eg, Crohn's, rheumatoid arthritis, or systemic lupus) resulting in end organ injury or requiring systemic and/or systemic disease-modifying agents within the last 90 days. Note: At least 90 days or 5 half-lives, whichever is shorter, must have elapsed after any prior immunosuppressive or immunomodulating therapy that impacts T-cell function and before leukapheresis.
  • History of concomitant genetic syndrome associated with bone marrow failure such as Fanconi anemia, Kostmann syndrome, or Shwachman-Diamond syndrome.
  • Any medical condition or residual toxicities from prior therapies per investigator assessment likely to interfere with the assessments of safety or efficacy of the study treatment.
  • History of a severe immediate hypersensitivity reaction or to any of the agents used in the study (including fludarabine and cyclophosphamide).
  • ≤ 6 weeks before randomization, during the treatment period, and until immune recovery following the study treatments (refer to Section 12.10 for additional country-specific requirements, as applicable).
  • Females of childbearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or have been postmenopausal for at least 2 years are not considered to be of childbearing potential.
  • Individuals of either sex who are not willing to practice highly effective from the time of through 12 months after the completion of KITE-753 or axi-cel infusion.
  • In the investigator's judgment, the individual is unlikely to complete all study-specific visits or procedures, including follow-up visits, or comply with the study requirements for participation.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Lymphodepleting Chemotherapy: KITE-753

    Participants with r/r LBCL will receive the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine and cyclophosphamide. * A single infusion at a target dose of anti-cluster of differentiation 19 (CD19)/CD20 chimeric antigen receptor (CAR) T cells/kg of KITE-753.

    Drug: KITE-753 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Lymphodepleting Chemotherapy: Axicabtagene Ciloleucel (axi-cel)

    Participants with r/r LBCL will receive the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine and cyclophosphamide. * A single infusion at a target dose of anti-CD19/CD20 CAR T cells/kg of axi-cel.

    Drug: Axicabtagene Ciloleucel · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

  • A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

  • Administered intravenously

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Proportion of Participants in Complete Response (CR) at Month 6

    Participants who would be in CR at Month 6 postinfusion of KITE-753 or axi-cel and prior to subsequent anti-lymphoma therapy. This will be assessed by the Lugano Classification by the blinded central assessment.

    Time frame: Month 6

  2. Event-free survival (EFS)

    EFS is defined as the time from randomization to the earliest occurrence of the following EFS events: a) Death due to any cause, b) Disease progression/relapse per blinded central assessment, and c) Initiation of any non-protocol specified subsequent anti-lymphoma therapy for the treatment of residual disease (including stable disease and partial response as per International Working Group (IWG) Lugano Response Criteria for Malignant Lymphoma).

    Time frame: Up to 36 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have achieved either CR or partial response (PR) by the Lugano Classification as determined by blinded central assessment after treatment completion and prior to subsequent anti-lymphoma therapy.

    Time frame: Up to 36 months

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to disease progression per the Lugano Classification as determined by blinded central assessment or death from any cause.

    Time frame: Up to 36 months

  3. Duration of Response (DOR)

    DOR is defined as the time from first objective response (CR or PR) prior to subsequent anti-lymphoma therapy to disease progression or death from any cause.

    Time frame: Up to 36 months

  4. Duration of Complete Response (DOCR)

    DOCR is defined as the time from first CR prior to subsequent anti-lymphoma therapy to disease progression or death from any cause.

    Time frame: Up to 36 months

  5. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death from any cause.

    Time frame: Up to 36 months

  6. Percentage of Participants Experiencing Adverse Events (AEs)

    Time frame: First dose date up to 36 months, plus 30 days

  7. Percentage of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: First dose date up to 36 months, plus 30 days

  8. Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Cancer-30 (EORTC-QLQ-C30)

    The EORTC-QLQ-C30 is a multi-item questionnaire measuring the following content: five (5) multi-item functional scales, three (3) multi-item symptom scales, six (6) single item symptoms scales, one (1) global health status scale, and one (1) global health-related quality of life (HRQoL). Each scale is measured from 0 to 100 after a linear transformation. Higher scores for functioning scales and for the Global Health Status or Global HRQoL scales indicate a higher level of functioning and a better HRQoL respectively, whereas higher scores in symptom scales represent a high level of symptoms.

    Time frame: Baseline, up to 36 months

  9. Changes From Baseline in the 5-level EuroQol 5 Dimensions Questionnaire (EQ-5D-5L) Score

    The EQ-5D-5L is a standard measure of health-related quality of life. The tool consists of the EQ-5D-5L descriptive part and the EQ visual analogue scale (VAS). The descriptive part comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each of these 5 dimensions has 5 levels (no problem, slight problems, moderate problems, severe problems, and extreme problems). Results for each of the 5 dimensions are combined into a 5-digit number to describe the participant's health state. The EQ-VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine." Higher scores of EQ VAS indicate better health.

    Time frame: Baseline, up to 36 months

  10. Changes From Baseline in the EuroQol Visual Analogue Scale (EQ-VAS) Score

    The EQ-VAS records the participant's self-rated health on a vertical VAS, where the end points were labeled "the best health you can imagine" and "the worst health you can imagine." The EQ-VAS could be used as a quantitative measure of a health outcome that reflected the participant's own judgment. The EQ-VAS recorded the participant's self-rated health on a vertical VAS, with a score numbered from 0 to 100, where '100 meant the best health you can imagine' and '0 meant the worst health you can imagine".

    Time frame: Baseline, up to 36 months

  11. Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ)-Non-Hodgkin's lymphoma (NHL)-Non-Hodgkin Lymphoma High Grade Module 29 (HG29)

    The EORTC QLQ-NHL-HG29 is a 29-item patient-reported assessment measuring patients' high-grade NHL-specific symptoms and functioning. The 29 items assess symptom burden due to disease and/or treatment, fatigue/physical condition, neuropathy, emotional impacts, and worries/fears health and functioning. Each scale is measured from 0 to 100 after a linear transformation. Higher scores for functional scales indicate a higher level of functioning and a better HRQoL, whereas higher scores in symptom scales represent a higher level of symptoms.

    Time frame: Baseline, up to 36 months

07

Study locations

42 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for May 2031, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartActual
May 22, 2026
Primary completionEst.
May 2031
CompletionEst.
May 2031
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 26, 2026
Sites
23 sites added — first sites in Belgium, France, Germany, Japan and Spain
Show 23 added (7 United States, 6 Spain, 2 Australia, 2 Belgium, 2 Japan, 2 United Kingdom, 1 France, 1 Germany)
  • University of Illinois · Chicago, United States
  • University of Maryland St. Joseph Medical Center · Baltimore, United States
  • Weill Cornell Medicine-NewYork-Presbyterian Hospital · New York, United States
  • Montefiore Medical Center · The Bronx, United States
  • Tennessee Oncology, PLLC - Investigational Drug Services · Nashville, United States
  • Inova Shar Cancer Institute · Fairfax, United States
  • Fred Hutchinson Cancer Center · Seattle, United States
  • Royal Prince Alfred Hospital · Camperdown, Australia
  • Concord Repatriation General Hospital · Sydney, Australia
  • Universitair Ziekenhuis Antwerpen · Edegem, Belgium
  • Universitair Ziekenhuis Gent · Ghent, Belgium
  • Hopital Saint Eloi · Montpellier, France
  • Universitatsklinikum Wurzburg · Würzburg, Germany
  • National Cancer Center Hospital · Tokyo, Japan
  • Toranomon Hospital · Tokyo, Japan
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Institut Catala d'Oncologia · Barcelona, Spain
  • Hospital General Universitario Gregorio Maranon · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Clinica Universidad de Navarra · Pamplona, Spain
  • Hospital Universitario de Salamanca · Salamanca, Spain
  • Cardiff and Vale University Health Board · Cardiff, United Kingdom
  • University College London Hospital NHS Foundation Trust · London, United Kingdom
Oct 8, 2026
Show all 2 updates
  1. Oct 26, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  2. Oct 8, 2026
    23 sites added — first sites in Belgium, France, Germany, Japan and Spain
    Show 23 added (7 United States, 6 Spain, 2 Australia, 2 Belgium, 2 Japan, 2 United Kingdom, 1 France, 1 Germany)
    • University of Illinois · Chicago, United States
    • University of Maryland St. Joseph Medical Center · Baltimore, United States
    • Weill Cornell Medicine-NewYork-Presbyterian Hospital · New York, United States
    • Montefiore Medical Center · The Bronx, United States
    • Tennessee Oncology, PLLC - Investigational Drug Services · Nashville, United States
    • Inova Shar Cancer Institute · Fairfax, United States
    • Fred Hutchinson Cancer Center · Seattle, United States
    • Royal Prince Alfred Hospital · Camperdown, Australia
    • Concord Repatriation General Hospital · Sydney, Australia
    • Universitair Ziekenhuis Antwerpen · Edegem, Belgium
    • Universitair Ziekenhuis Gent · Ghent, Belgium
    • Hopital Saint Eloi · Montpellier, France
    • Universitatsklinikum Wurzburg · Würzburg, Germany
    • National Cancer Center Hospital · Tokyo, Japan
    • Toranomon Hospital · Tokyo, Japan
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Institut Catala d'Oncologia · Barcelona, Spain
    • Hospital General Universitario Gregorio Maranon · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Clinica Universidad de Navarra · Pamplona, Spain
    • Hospital Universitario de Salamanca · Salamanca, Spain
    • Cardiff and Vale University Health Board · Cardiff, United Kingdom
    • University College London Hospital NHS Foundation Trust · London, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07479797
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
May 22, 2026
Primary completion
May 2031 (estimated)
Completion
May 2031 (estimated)
Last update
Oct 26, 2026

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753 · Axicabtagene ciloleucel

Start the discussion